Background: In PRONTO-Pump-2, a Phase 3, 16-week, randomized, double-blind clinical trial in patients with type 1 diabetes on continuous subcutaneous insulin infusion, ultra rapid lispro (URLi) showed superior postprandial glucose control and noninferior HbA1c reduction, with less hypoglycemia compared to Humalog® (Lispro). Although primarily reported as mild in severity, incidence of infusion site reactions was higher with URLi compared to Humalog (37.7% vs. 10.1%). We assessed patient-reported health status in the PRONTO-Pump-2 trial as an exploratory measure.

Methods: The EQ-5D-5L (which includes a visual analogue scale rating perceived health [VAS; 0-100 from worst to best imaginable health state]) was administered at baseline and endpoint (week 16 or early discontinuation) to patients on URLi (N=215) or Humalog (N=217). The EQ-5D-5L assesses 5 dimensions of health status (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) for which a health state index score ranging from less than 0 (worse than death) to 1 (perfect health) is calculated. Change from baseline to endpoint (last observation carried forward) in scores was analyzed using an ANCOVA model.

Results: At endpoint, mean health state index scores showed no significant differences between treatments (URLi, 0.88 [standard error 0.009]; Humalog, 0.89 [0.009]) with an increase from baseline of +0.01 (0.009) within each treatment. On the dimension of pain/discomfort, distribution of responses was similar between treatments. Endpoint VAS scores were also similar between URLi and Humalog (80.2 [0.82] and 80.8 [0.78], respectively) but decreased from baseline within each treatment: URLi, -1.1 (0.82); Humalog -0.5 (0.78).

Conclusion: In PRONTO-Pump-2, the EQ-5D-5L indicated no differences in health status, including the pain/discomfort dimension, between patients on URLi versus Humalog, despite more frequent reports of infusion site reactions with URLi treatment.

Disclosure

R. Paczkowski: Employee; Self; Eli Lilly and Company, Employee; Spouse/Partner; Amgen Inc., Stock/Shareholder; Self; Eli Lilly and Company, Stock/Shareholder; Spouse/Partner; Amgen Inc. C. Piras de oliveira: Employee; Self; Eli Lilly and Company, Stock/Shareholder; Self; Eli Lilly and Company. J. Cho: None. A. Goldyn: Employee; Self; Eli Lilly and Company. J. Poon: Employee; Self; Eli Lilly and Company. E. R. Hankosky: Employee; Self; Eli Lilly and Company, Stock/Shareholder; Self; Eli Lilly and Company. D. A. Ignaut: Employee; Self; Eli Lilly and Company.

Funding

Eli Lilly and Company

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.